Veradermics (NYSE: MANE) will present results from its Phase 2/3 clinical trial of VDPHL01 at the 2026 World Congress for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE